Zacks Investment Research Downgrades Exponent (NASDAQ:EXPO) to Hold

Zacks Investment Research downgraded shares of Exponent (NASDAQ:EXPO) from a buy rating to a hold rating in a report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Exponent, Inc., is a multidisciplinary organization of scientists, physicians, engineers and business consultants performing in-depth scientific research and analysis in over 90 technical disciplines. The company is an engineering and scientific consulting firm providing solutions to complex problems. The firm has been best known for analyzing accidents and failures to determine their causes, but in recent years it has become more active in assisting clients with human health, environmental and engineering issues associated with new products to help prevent problems in the future. The Company serves clients in the automotive, aviation, chemical, construction, consumer products, energy, government, health, insurance, manufacturing, technology and other sectors. “

Several other analysts also recently commented on the stock. Cantor Fitzgerald upped their price target on shares of Exponent from $64.00 to $73.00 and gave the company an overweight rating in a research report on Friday, July 19th. BidaskClub downgraded shares of Exponent from a buy rating to a hold rating in a research report on Tuesday, September 10th. SunTrust Banks set a $70.00 price target on shares of Exponent and gave the company a buy rating in a research report on Friday, July 19th. ValuEngine upgraded shares of Exponent from a sell rating to a hold rating in a research report on Wednesday, September 4th. Finally, DA Davidson assumed coverage on shares of Exponent in a research report on Wednesday, August 28th. They issued a neutral rating for the company. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $76.67.



EXPO stock opened at $70.73 on Wednesday. The company has a fifty day moving average price of $69.92 and a 200 day moving average price of $61.10. Exponent has a 12 month low of $44.44 and a 12 month high of $72.70. The company has a market cap of $3.72 billion, a price-to-earnings ratio of 56.58 and a beta of 0.43. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.60 and a quick ratio of 3.60.

Exponent (NASDAQ:EXPO) last released its quarterly earnings results on Thursday, July 18th. The business services provider reported $0.39 EPS for the quarter, beating the consensus estimate of $0.33 by $0.06. Exponent had a net margin of 19.64% and a return on equity of 23.44%. The firm had revenue of $106.50 million during the quarter, compared to the consensus estimate of $95.77 million. During the same quarter in the prior year, the firm earned $0.34 EPS. Exponent’s revenue for the quarter was up 11.4% on a year-over-year basis. As a group, analysts anticipate that Exponent will post 1.47 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Friday, September 6th were given a $0.16 dividend. The ex-dividend date was Thursday, September 5th. This represents a $0.64 annualized dividend and a yield of 0.90%. Exponent’s dividend payout ratio (DPR) is 51.20%.

In other Exponent news, CFO Richard L. Schlenker, Jr. sold 22,243 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $70.57, for a total transaction of $1,569,688.51. Following the completion of the transaction, the chief financial officer now owns 247,118 shares in the company, valued at approximately $17,439,117.26. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John Pye sold 3,000 shares of the company’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $70.31, for a total transaction of $210,930.00. Following the transaction, the insider now owns 25,747 shares of the company’s stock, valued at approximately $1,810,271.57. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 102,773 shares of company stock valued at $7,227,536. 2.30% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC grew its stake in shares of Exponent by 787.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 612 shares of the business services provider’s stock worth $36,000 after purchasing an additional 543 shares during the period. Bremer Bank National Association acquired a new position in shares of Exponent during the 1st quarter worth $55,000. NN Investment Partners Holdings N.V. acquired a new position in shares of Exponent during the 2nd quarter worth $91,000. Atria Investments LLC acquired a new position in shares of Exponent during the 2nd quarter worth $115,000. Finally, Cim LLC acquired a new position in shares of Exponent during the 2nd quarter worth $200,000. Institutional investors own 88.08% of the company’s stock.

Exponent Company Profile

Exponent, Inc, together with its subsidiaries, operates as a science and engineering consulting company worldwide. Its services include analysis of product development, product recall, regulatory compliance, and the discovery of potential problems related to products, people, property, and impending litigation.

Featured Story: What is a stock portfolio tracker?

Get a free copy of the Zacks research report on Exponent (EXPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.